The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study

References

• Folkman J. What is the evidence that tumors are angiogenesis dependent? JNCI. 1990;82(1):4–7.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Amini A, Masoumi Moghaddam S, L Morris D, H Pourgholami M. The critical role of vascular endothelial growth factor in tumor angiogenesis. CCDT. 2012;12(1):23–43.
   Web of Science ®Google Scholar
• Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611.
   PubMed Web of Science ®Google Scholar
• Rajabi M, Mousa S. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(4):34.
   PubMed Web of Science ®Google Scholar
• Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res. 2007;74(2-3):85–89.
   PubMed Web of Science ®Google Scholar
• El‐Kenawi AE, El‐Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170:712–729.
   PubMed Web of Science ®Google Scholar
• Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leukemia Res. 2009;33(5):638–644.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–2049.
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Angiogenesis: tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401.
   PubMed Web of Science ®Google Scholar
• Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood. 2008;111(3):1227–1233.
   PubMed Web of Science ®Google Scholar
• Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2(12):758–770.
   PubMed Web of Science ®Google Scholar
• Lal N, Puri K, Rodrigues B. Vascular endothelial growth factor B and its signaling. Front Cardiovasc Med. 2018;5:39.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669.
   PubMed Web of Science ®Google Scholar
• Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97(7):978.
   PubMed Web of Science ®Google Scholar
• Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther. 2006;5(5):1099–1107.
   PubMed Web of Science ®Google Scholar
• Pourgholami MH, Khachigian LM, Fahmy RG, Badar S, Wang L, Chu SWL, Morris DL. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun. 2010;397(4):729–734.
   PubMed Web of Science ®Google Scholar
• Zang J, Hu Y, Xu X, Ni J, Yan D, Liu S, He J, Xue J, Wu J, Feng J, et al. Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer. OTT. 2017;10:409.
   Web of Science ®Google Scholar
• Sun C, Li H-L, Chen H-R, Shi M-L, Liu Q-h, Pan Z-Q, Bai J, Zheng J-N. Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma. Sci Rep. 2015;5(1):9774.
   PubMed Web of Science ®Google Scholar
• Rafii S, Butler JM, Ding B-S. Angiocrine functions of organ-specific endothelial cells. Nature. 2016;529(7586):316.
   PubMed Web of Science ®Google Scholar
• Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Nat Acad Sci. 1998;95(7):3609–3614.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. JCO. 2005;23(5):1011–1027.
   PubMed Web of Science ®Google Scholar
• Seidel C, Florean C, Schnekenburger M, Dicato M, Diederich M. Chromatin-modifying agents in anti-cancer therapy. Biochimie. 2012;94(11):2264–2279.
   PubMed Web of Science ®Google Scholar
• Hong YS, Nam B-H, Kim K-P, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim T-Y, Kim JH, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–1253.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714.
   PubMed Web of Science ®Google Scholar
• Ochwang’i DO, Kimwele CN, Oduma JA, Gathumbi PK, Mbaria JM, et al. Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. J Ethnopharmacol. 2014;151:1040–1055.
   PubMed Web of Science ®Google Scholar
• Greenwell M, Rahman P. Medicinal plants: their use in anticancer treatment. Int J Pharm Sci Res. 2015;6(10):4103.
   PubMed Web of Science ®Google Scholar
• Safarzadeh E, Shotorbani SS, Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull. 2014;4:421.
   PubMedGoogle Scholar
• Yin S-Y, Wei W-C, Jian F-Y, Yang N-S. Therapeutic applications of herbal medicines for cancer patients. Evid-Based Complementary Altern Med. 2013;2013:1.
   Web of Science ®Google Scholar
• Fouché G, Cragg G, Pillay P, Kolesnikova N, Maharaj V, Senabe J. In vitro anticancer screening of South African plants. J Ethnopharmacol. 2008;119:455–461.
   PubMed Web of Science ®Google Scholar
• Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res. 2009;15(8):2594–2601.
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689.
   PubMed Web of Science ®Google Scholar
• Fan T-P, Yeh J-C, Leung KW, Yue PY, Wong RN. Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci. 2006;27(6):297–309.
   PubMed Web of Science ®Google Scholar
• El Hasasna H, Athamneh K, Al Samri H, Karuvantevida N, Al Dhaheri Y, Hisaindee S, Ramadan G, Al Tamimi N, AbuQamar S, Eid A, et al. Rhus coriaria induces senescence and autophagic cell death in breast cancer cells through a mechanism involving p38 and ERK1/2 activation. Sci Rep. 2015;5(1):13013.
   PubMed Web of Science ®Google Scholar
• Cragg GM, Kingston DG, Newman DJ. Anticancer agents from natural products. Boca Raton, FL: CRC Press, 2011.
   Google Scholar
• Ham SY, Kwon T, Bak Y, Yu J-H, Hong J, Lee SK, Yu D-Y, Yoon D-Y. Mucin 1-mediated chemo-resistance in lung cancer cells. Oncogenesis. 2016;5(1):e185.
   PubMed Web of Science ®Google Scholar
• Li W, Tang Y-X, Wan L, Cai J-H, Zhang J. Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncol Lett. 2013;5(3):923–928.
   PubMed Web of Science ®Google Scholar
• Braakhuis BJ, Hill BT, Dietel M, Kelland LR, Aapro MS, Zoli W, Lelieveld P. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res. 1994;14(1A):205–208.
   PubMed Web of Science ®Google Scholar
• Nogales E. Structural insights into microtubule function. Annu Rev Biophys Biomol Struct. 2001;30(1):397–420.
   PubMedGoogle Scholar
• McGrail DJ, Khambhati NN, Qi MX, Patel KS, Ravikumar N, Brandenburg CP, Dawson MR. Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner. Sci Rep. 2015;5(1):9529.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin cell Biol. 1998;10(1):123–130.
   PubMed Web of Science ®Google Scholar
• Myoung H, Hong S-D, Kim Y-Y, Hong S-P, Kim M-J. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett. 2001;163(2):191–200.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Carré M, Pourroy B, Camoin L, Rebaï O, Briand C, Braguer D. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Therapeut. 2004;3(10):1301–1310.
   PubMed Web of Science ®Google Scholar
• Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2(11):1843–1849.
   PubMed Web of Science ®Google Scholar
• Xu G, Pan J, Martin C, Yeung S-C. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metabol. 2001;86:1769–1777.
   PubMed Web of Science ®Google Scholar
• Guo X-L, Lin G-J, Zhao H, Gao Y, Qian L-P, San-Rong X, Li-Na F, Qing X, Jie-Jun W. Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell. WJG. 2003;9(9):1995.
   PubMed Web of Science ®Google Scholar
• Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by Docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center 1 supported by grants from the National Cancer Institute (grants R01-CA54422, RO1-CA89352, and P01-CA13330). Aventis Pharmaceuticals, and UJA-Federation of New York. 1. Mol Cancer Therapeut. 2002;1:1191–1200.
   PubMed Web of Science ®Google Scholar
• Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1–2):72–79.
   PubMed Web of Science ®Google Scholar
• Moudi M, Go R, Yien CYS, Nazre M. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231.
   PubMedGoogle Scholar
• Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. JCO. 2007;25(23):3495–3502.
   PubMed Web of Science ®Google Scholar
• Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(2):41–59.
   PubMed Web of Science ®Google Scholar
• Prakash O, Kumar A, Kumar P. Anticancer potential of plants and natural products. AJPS. 2013;1:104–115.
   Google Scholar
• Jordan M. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. CMCACA. 2012;2(1):1–17.
   Google Scholar
• Ganugapati J, Mukundan M, Mandava A, Ahuja SJ. Insilico analysis of vinca alkaloids as antimitotic and anti-microtubule agents: a potential cure for cancer. Int J Pharm Sci Drug Res. 2015;6:2841–2845.
   Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253.
   PubMed Web of Science ®Google Scholar
• Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94(12):4143–4155.
   PubMed Web of Science ®Google Scholar
• Albertsson P, Lennernäs B, Norrby K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol. 2006;45(2):144–155.
   PubMed Web of Science ®Google Scholar
• Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res. 2007;13(13):3977–3988.
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42(16):2821–2832.
   PubMed Web of Science ®Google Scholar
• Kapoor L. Handbook of ayurvedic medicinal plants: Herbal reference library. Abingdon, UK: Routledge, 2017.
   Google Scholar
• Liu Y-Q, Li W-Q, Morris-Natschke SL, Qian K, Yang L, Zhu G-X, Wu X-B, Chen A-L, Zhang S-Y, Nan X, et al. Perspectives on biologically active camptothecin derivatives. Med Res Rev. 2015;35(4):753–789.
   PubMed Web of Science ®Google Scholar
• Hagmann R, Hess V, Zippelius A, Rothschild SI. Second-line therapy of small-cell lung cancer: topotecan compared to a combination treatment with adriamycin, cyclophosphamide and vincristine (ACO)-a single center experience. J Cancer. 2015;6(11):1148.
   PubMed Web of Science ®Google Scholar
• Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003;88(3):335:
   PubMed Web of Science ®Google Scholar
• Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003;21(2):291–297.
   PubMed Web of Science ®Google Scholar
• Srinivasan R, Lakshmana G, Anjinayalu B, Anil Kumar D, Shalem Raju K. Naturevolution effective against cancer therapy–Review. Int J Pharm Bio Sci. 2014;5:357–365.
   Google Scholar
• Wang J, Zhang Y, Hou Y, Li J, He X. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev. 2010;2:CD008593.
   Google Scholar
• Zou J, Li S, Chen Z, Lu Z, Gao J, Zou J, Lin X, Li Y, Zhang C, Shen L. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. Cell death Dis. 2018;9(6):661:
   PubMed Web of Science ®Google Scholar
• Woo JH, Shimoni Y, Yang WS, Subramaniam P, Iyer A, Nicoletti P, Rodríguez Martínez M, López G, Mattioli M, Realubit R, et al. Elucidating compound mechanism of action by network perturbation analysis. Cell. 2015;162(2):441–451.
   PubMed Web of Science ®Google Scholar
• Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, Zunino F. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol. 2004;67(6):1035–1045.
   PubMed Web of Science ®Google Scholar
• Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer. 2002;98(1):36–41.
   PubMed Web of Science ®Google Scholar
• Grundmann E, Höffken K. Journal of cancer research and clinical oncology. In: Verleger• Humanist Homme de Lettres. Berlin, Germany: Springer; 2001, p. 72–73.
   Google Scholar
• Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, et al. Antiangiogenic Effects of the Novel Camptothecin ST1481 (Gimatecan) in Human Tumor Xenografts11Associazione Italiana Ricerca sul Cancro, Milan; the Ministero della Salute, Rome; the Consiglio Nazionale delle Ricerche, Rome; and the Fondazione Thomas Hoepli. Mol Cancer Res. 2003;1:863–870. :
   PubMed Web of Science ®Google Scholar
• Sun L-C, Luo J, Mackey VL, Fuselier JA, Coy DH. Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anti-cancer Drugs. 2007;18(3):341–348.
   PubMed Web of Science ®Google Scholar
• Lin C-J, Lin Y-L, Luh F, Yen Y, Chen R-M. Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis. Oncotarget. 2016;7(27):42408
   PubMedGoogle Scholar
• Issell BF. The podophyllotoxin derivatives VP16-213 and VM26. Cancer Chemother Pharmacol. 1982;7(2-3):73–80.
   PubMed Web of Science ®Google Scholar
• Kumar D, George VC, Suresh P, Kumar RA. Cytotoxicity, apoptosis induction and anti-metastatic potential of Oroxylum indicum in human breast cancer cells. Asian Pac J Cancer Prev. 2012;13(6):2729–2734.
   PubMedGoogle Scholar
• Newlands E, Bagshawe K. Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinoma. Eur J Cancer (1965). 1980;16(3):401–405.
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. JCO. 1998;16(2):405–410.
   PubMed Web of Science ®Google Scholar
• Shoeb M. Anti-cancer agents from medicinal plants. Bangladesh J Pharmacol. 2006;1:35–41.
   Google Scholar
• Van Maanen J, Retel J, De Vries J, Pinedo H. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst. 1988;80(19):1526–1533.
   PubMed Web of Science ®Google Scholar
• Sang C-Y, Xu X-H, Qin W-W, Liu J-F, Hui L, et al. DPMA, a deoxypodophyllotoxin derivative, induces apoptosis and anti-angiogenesis in non-small cell lung cancer A549 cells. Bioorg Med Chem Lett. 2013;23:6650–6655.
   PubMed Web of Science ®Google Scholar
• Kamal A, Tamboli JR, Ramaiah MJ, Adil SF, Pushpavalli SNCVL, Ganesh R, Sarma P, Bhadra U, Pal-Bhadra M. Quinazolino linked 4β-amidopodophyllotoxin conjugates regulate angiogenic pathway and control breast cancer cell proliferation. Bioorg Med Chem. 2013;21(21):6414–6426.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Wu M, Miao J, Duan H, Zhang S, Chen M, Sun L, Wang Y, Zhang X, Zhu X, et al. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects. Int J Biochem Cell Biol. 2013;45(8):1710–1719.
   PubMed Web of Science ®Google Scholar
• Sun Q, Li S, Li J, Fu Q, Wang Z, Li B, Liu S-S, Su Z, Song J, Lu D, et al. Homoharringtonine regulates the alternative splicing of Bcl-x and caspase 9 through a protein phosphatase 1-dependent mechanism. BMC Complement Altern Med. 2018;18(1):164.
   PubMed Web of Science ®Google Scholar
• Xiu-Jin Y, Mao-Fang L. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ-Sc A. 2004;5:230–234.
   Google Scholar
• Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep. 2015;5:8477.
   PubMed Web of Science ®Google Scholar
• Jeong S-J, Koh W, Lee E-O, Lee H-J, Lee H-J, Bae H, Lü J, Kim S-H. Antiangiogenic phytochemicals and medicinal herbs. Phytother Res. 2011;25(1):1–10.
   PubMed Web of Science ®Google Scholar
• Karthikeyan K, Gunasekaran P, Ramamurthy N, Govindasamy S. Anticancer activity of Ocimum sanctum. Pharmaceut Biol. 1999;37(4):285–290.
   Web of Science ®Google Scholar
• Aggarwal A, Mali RR. Ocimum tenuiflorum–a medicinal plants with its versatile uses. IJARSt. 2015;2(2):1–10.
   Google Scholar
• Sivalokanathan S, Ilayaraja M, Balasubramanian M. Efficacy of Terminalia arjuna (Roxb.) on N-nitrosodiethylamine induced hepatocellular carcinoma in rats. Indian J Exp Biol. 2005;43(3):264–267.
   PubMedGoogle Scholar
• Kapoor L. CRC handbook of ayurvedic medicinal plants. Boca Raton, FL: CRC Press, 2018.
   Google Scholar
• Prabhu VV, Chidambaranathan N, Gopal V. Evaluation and quantification of angiogenesis activity of Terminalia bellirica roxb, by mice sponge implantation method. J Young Pharm. . 2012;4(1):22–27.
   PubMedGoogle Scholar
• Kokate C, Purohit A, Gokhale S. Text book pharmacognosy, published by Nirali Prakashan. Punne. 1999;11:92–94.
   Google Scholar
• Tan M, Kuroyanagi M, Sulaiman S, Najimudin N, Muhammad TT. Cytotoxic activities of major diterpenoid constituents of Andrographis paniculata. in a panel of human tumor cell lines. Pharmaceut Biol. 2005;43(6):501–508.
   Web of Science ®Google Scholar
• Dai J, Lin Y, Duan Y, Li Z, Zhou D, Chen W, Wang L, Zhang Q-Q. Andrographolide inhibits angiogenesis by inhibiting the Mir-21-5p/TIMP3 signaling pathway. Int J Biol Sci. 2017;13(5):660.
   PubMed Web of Science ®Google Scholar
• Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris: Lavoisier Publishing; 1995.
   Google Scholar
• Subedi T. Phytochemical studies of taxus species and their uses in cancer treatment. Janapriya J Interdisciplinary Stud. 2018;6:160–171.
   Google Scholar
• Kalpana S, Lokesh K, Juvatkar P, Shukla V, Manvi F. Plant products potential as anti-angiogenic and in cancer management. Int J Res Ayurveda Pharm. 2010;1:339–349.
   Google Scholar
• Sayeed M, Jesmin MH, Sarker T, Rahman M, Alam M. Antitumor activity of leaf extracts of Catharanthus roseus (L.) G. Don. Plant Environment development. 2014;3:24–30
   Google Scholar
• Lawal OA, Ogunwande IA, Ibirogba AE, Layode OM, Opoku AR. Chemical constituents of essential oils from Catharanthus roseus (L.) G. Don grown in Nigeria. J Essen Oil Bear Plants. 2015;18(1):57–63.
   Web of Science ®Google Scholar
• Glen H. Guide to trees introduced into Southern Africa. Johannesburg: Penguin Random House South Africa, 2016.
   Google Scholar
• Cordell GA. The alkaloids: chemistry and biology. Cambridge, MA: Academic Press, 2008.
   Google Scholar
• Giri A, Narasu ML. Production of podophyllotoxin from Podophyllum hexandrum: a potential natural product for clinically useful anticancer drugs. Cytotechnology. 2000;34(1/2):17–26.
   PubMed Web of Science ®Google Scholar
• Rust R, Roth R. Seed production and seedling establishment in the mayapple, Podophyllum peltatum L. Am Midl Nat. 1981;105(1):51–60.
   Web of Science ®Google Scholar
• da Silveira Vasconcelos M, Mota EF, Gomes-Rochette NF, Nunes-Pinheiro DCS, Nabavi SM, et al. Ginger (Zingiber officinale Roscoe). In: Nonvitamin and nonmineral nutritional supplements. Amsterdam: Elsevier, Academic Press, 2019, p. 235–239.
   Google Scholar
• Ansari JA, Ahmad MK, Khan AR, Fatima N, Khan HJ, et al. Anticancer and antioxidant activity of Zingiber officinale Roscoe rhizome. Indian J Exp Biol. 2016;54(11):767–773.
   PubMed Web of Science ®Google Scholar
• Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J, Liu JR. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med. 2007;7:44.
   PubMedGoogle Scholar
• Koo HJ, Gang DR. Suites of terpene synthases explain differential terpenoid production in ginger and turmeric tissues. PloS One. 2012;7(12):e51481.
   PubMed Web of Science ®Google Scholar
• Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 2008;57(11):1509–1517.
   PubMed Web of Science ®Google Scholar
• Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting β-catenin-mediated transactivation and cell–cell adhesion pathways. Histochem J. 2003;35(3):301–307.
   Google Scholar
• Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Therapy. 2003;2:126–132.
   Web of Science ®Google Scholar
• Lee B-C, Doo H-K, Lee H-J, Jin S-Y, Jung J-H, Hong S-J, Lee S-H, Kim S-D, Park J-K, Leem K-H, et al. The inhibitory effects of aqueous extract of Magnolia officinalis on human mesangial cell proliferation by regulation of platelet-derived growth factor-BB and transforming growth factor-β1 expression. J Pharmacol Sci. 2004;94(1):81–85.
   PubMed Web of Science ®Google Scholar
• Son HJ, Lee HJ, Yun-Choi HS, Ryu J-H. Inhibitors of nitric oxide synthesis and TNF-α expression from Magnolia obovata in activated macrophages. Planta Med. 2000;66(5):469–471.
   PubMed Web of Science ®Google Scholar
• Ríos J-L. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 2011;77(07):681–691.
   PubMed Web of Science ®Google Scholar
• Huang KC. The pharmacology of Chinese herbs. Abingdon, UK: Routledge, 1998.
   Google Scholar
• Meade-Tollin LC, Wijeratne EMK, Cooper D, Guild M, Jon E, Fritz A, Zhou G-X, Whitesell L, Liang J-y, Gunatilaka AAL, et al. Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J Nat Prod. 2004;67(1):2–4.
   PubMed Web of Science ®Google Scholar
• Zhang L, Rui Y-C, Yang P-Y, Qiu Y, Li T-J, Liu H-C. Inhibitory effects on Ginkgo biloba extract on vascular endothelial growth factor in rat aortic endothelial cells. Acta Pharmacol Sin. 2002;23(10):919–923.
   PubMed Web of Science ®Google Scholar
• DeFeudis FV, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fund Clin Pharmacol. 2003;17(4):405–417.
   PubMed Web of Science ®Google Scholar
• Chan P-C, Xia Q, Fu PP. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci health part C. 2007;25(3):211–244.
   Web of Science ®Google Scholar
• Harmsma M, Grommé M, Ummelen M, Dignef W, Tusenius KJ, et al. Differential effects of Viscum album extract Iscador® Qu on cell cycle progression and apoptosis in cancer cells. Int J Oncol. 2004;25:1521–1529.
   PubMed Web of Science ®Google Scholar
• Elluru SR, Duong Van Huyen J-P, Delignat S, Prost F, Heudes D, Kazatchkine MD, Friboulet A, Kaveri SV. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res. 2009;29(8):2945–2950.
   PubMed Web of Science ®Google Scholar
• Barnes J, Anderson LA, Phillipson JD, Newall CA. Herbal medicines. London: Pharmaceutical Press, 2007.
   Google Scholar
• Sagar SM, Yance D, Wong R. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—part 1. Curr Oncol. 2006;13(1):14.
   PubMedGoogle Scholar
• Lee D-W, Liu Y. Molecular Structure and Stereochemistry of Silybin A, Silybin B, Isosilybin A, and Isosilybin B, Isolated from Silybum marianum (Milk Thistle). J Nat Prod. 2003;66:1171–1174.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S. Milk thistle (Silybum marianum L. Gaert.) seeds in health In: Nuts and seeds in health and disease prevention. London, Burlington, San Diego : Academic Press; 2011. p. 759–766
   Google Scholar
• Datta A, Ghosh AK. Probable natural sources of antiangiogenic agents. Int. J Appl Biol. 2010;1: 1271–1278.
   Google Scholar
• De A, Powers B, De A, Zhou J, Sharma S, Van Veldhuizen P, Bansal A, Sharma R, Sharma M. Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells. Oncotarget. 2016;7(21):31484.
   PubMedGoogle Scholar
• Nagaraj SRM, Lingaraj SM, Balaraju Y, Kumar A, Salimath BP. MTA1 induced angiogenesis, migration and tumor growth is inhibited by Glycyrrhiza glabra. IOSR J Pharm. 2012;2:24–30.
   Google Scholar
• Nangia‐Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, et al. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer. 2007;121:884–894.
   PubMed Web of Science ®Google Scholar
• Abdul W, Hajrah NH, Sabir JM, Al-Garni SM, Sabir MJ, Kabli SA, Saini K, Bora R. Therapeutic role of Ricinus communis L. and its bioactive compounds in disease prevention and treatment. Asian Pac J Trop Med. 2018;11(3):177.
   Web of Science ®Google Scholar
• Muthuraman MS, Sinsinwar S, Vetrivel U. Anticancer activity of Sida cordifolia L.–Insilico approach. J Pharmaceut Sci Res. 2017;9:1363.
   Google Scholar
• Prashanth VK, Shashidhara S, Kumar M, Sridhara B. Cytoprotective role of Solanum nigrum against gentamicin-induced kidney cell (Vero cells) damage in vitro. Fitoterapia. 2001;72:481–486.
   PubMed Web of Science ®Google Scholar
• Mathur R, Gupta SK, Singh N, Mathur S, Kochupillai V, Velpandian T. Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J Ethnopharmacol. 2006;105(3):336–341.
   PubMed Web of Science ®Google Scholar
• Chen H-H, Zhou H-J, Wu G-D, Lou X-E. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 2004;71(1):1–9.
   PubMed Web of Science ®Google Scholar
• Rombauts K, Heyerick A. Consortium C-C: Artemisia annua. Dostupné na: http://www.cam-cancer.org/The-Summaries/Herbal-products/Artemisia-annua, 2011.
   Google Scholar
• Liu JJ, Huang TS, Cheng WF, Lu FJ. Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer. 2003;106(4):559–565.
   PubMed Web of Science ®Google Scholar
• Li H-B, Chen F. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatograph A. 2005;1074(1–2):107–110.
   PubMed Web of Science ®Google Scholar
• Yang J, Wu X, Yu H, Liao X, Teng L. NMDA receptor-mediated neuroprotective effect of the Scutellaria baicalensis Georgi extract on the excitotoxic neuronal cell death in primary rat cortical cell cultures. Sci World J. 2014; 2014:459549.
   Google Scholar
• Lin M-T, Yen M-L, Lin C-Y, Kuo M-L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 2003;64(5):1029–1036.
   PubMed Web of Science ®Google Scholar
• Khanna S, Roy S, Bagchi D, Bagchi M, Sen CK. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Rad Biol Med. 2001;31(1):38–42.
   PubMed Web of Science ®Google Scholar
• Nassiri‐Asl M, Hosseinzadeh H. Review of the pharmacological effects of Vitis vinifera (Grape) and its bioactive compounds. Phytother Res. 2009;23:1197–1204.
   PubMed Web of Science ®Google Scholar
• Vidya T, Julkarni KS. Beneficial effict of green tea with special reference to neuropathy: review and pilot trial. Anc Sci Life. 2002;22(1):41.
   PubMedGoogle Scholar
• Rashidi B, Malekzadeh M, Goodarzi M, Masoudifar A, Mirzaei H. Green tea and its anti-angiogenesis effects. Biomed Pharmacotherap. 2017;89:949–956.
   PubMed Web of Science ®Google Scholar
• Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009;23(5):289–304.
   PubMed Web of Science ®Google Scholar
• Socinski M, Novello S, Sanchez J, Brahmer J, Govindan R, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. J Clin Oncol. 2006;24:7001–7001.
   Web of Science ®Google Scholar
• Kulke M, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Baum CM, Fuchs CS, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). JCO. 2005;23(16_suppl):4008–4008.
   Web of Science ®Google Scholar
• Abdulghani J, Gokare P, Gallant J-N, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, et al. Sorafenib and quinacrine target anti-apoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer (ATC). Clin Cancer Res. 2016;22(24):6192–6203.
   PubMed Web of Science ®Google Scholar
• Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs (London, England: 2000). 2008;9:658–671.
   PubMed Web of Science ®Google Scholar
• Faes S, Santoro T, Demartines N, Dormond O. Evolving significance and future relevance of anti-angiogenic activity of mTOR inhibitors in cancer therapy. Cancers. 2017;9(12):152.
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549–557.
   PubMed Web of Science ®Google Scholar